The role of serologic biomarkers "liquid biopsy" in the fight against breast cancer: From biological foundations to clinical impact.
Blood-based cancer biomarkers show promise for breast cancer detection and monitoring, though standardized testing protocols still need refinement for routine use.
Serologic liquid biopsy biomarkers (ctDNA, cfDNA, exosomes, CTCs, protein markers) span from discovery to clinical implementation in breast cancer, with current gaps in standardisation and prospective validation limiting routine adoption. This record was retained from the prior triage attempt for PubMed pipeline handoff.
What the study was
- Study design
- narrative_review
- Category
- early_cancer_detection
- Maturity
- Validated
- Journal
- iScience
Why it surfaced
Comprehensive liquid biopsy review in breast cancer from open-access iScience; useful pipeline context but limited by narrative review design with no new data.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.